Envoy Medical Reaches Key FDA Milestone for Fully Implanted Hearing Device

Envoy Medical (NASDAQ: COCH) has announced the submission of the first module of its Modular Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its Breakthrough Device-designated fully implanted hearing solution. The submission marks the first regulatory milestone in the company’s planned modular approval strategy.

Unlike a traditional PMA submission, the modular pathway allows Envoy Medical to submit completed sections for FDA review as they become available, helping streamline the regulatory process. The company expects to submit a total of four modules, with the final module—including clinical trial data—targeted for submission during the second quarter of 2027.

#EnvoyMedical
#COCH
#HearingHealth
#MedicalDevices
#FDA
#BreakthroughDevice
#HealthcareInnovation
#Biotech
#MedicalTechnology
#HearingLoss
#ClinicalTrials
#LifeSciences
#NASDAQ
#JaneKing
#NewsOut